Open Nav

Satsuma Pharmaceuticals, Inc.

  • John Kollins, Satsuma Pharmaceuticals, Inc.

Raise Series B capital fund Phase 3 efficacy study

  • Date:Wednesday, October 17
  • Time:3:00 PM - 3:15 PM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Satsuma Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing STS101, a potential best-in-class therapy for acute migraine. STS101 combines the gold-standard anti-migraine drug, dihydroergotamine (DHE), with unique and proprietary dry-powder nasal formulation and drug delivery device technologies that enable rapid absorption with high bioavailability of drugs delivered via the nose. DHE has multiple therapeutic advantages over other migraine therapies but is not currently available in a fast-acting, patient-friendly, non-injectable preparation. STS101 has undergone extensive preclinical optimization and evaluation. Based on pharmacokinetic data generated to date, Satsuma anticipates STS101 will be highly effective and well-tolerated in a large number of migraine sufferers whose needs are not well served with current therapies, including those with difficult-to-treat migraine types.
  • Company
  • Company HQ City:South San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:John Kollins
  • Year Founded:2016
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :STS101 dihydroergotamine nasal powder for acute migraine
  • Development Phase of Primary Product:Phase I
  • Previous and Current Investors:RA Capital, TPG Biotech, Shin Nippon Biomedical Laboratories, Ltd.
  • Size of Last Investment Round:$12M
  • Total Amount Raised to Date, In All Rounds:$12.1M
John Kollins
Satsuma Pharmaceuticals, Inc.